Prostate Cancer Diagnosis and Treatment
Prostate cancer is the most commonly diagnosed solid malignancy in men across much of the world, and understanding how to detect it early and treat it effectively has occupied clinicians and researchers for decades. Work in this area spans the full clinical arc of the disease: from PSA-based screening and MRI-guided biopsy through histological grading with the Gleason system, to treatment with radiation therapy, surgery, or androgen suppression, and on to tracking long-term survival in diverse patient populations. A central tension driving current research is how to distinguish slow-growing tumors that may never threaten a patient's life from aggressive cancers that demand prompt intervention—overdiagnosis and overtreatment carry real costs in quality of life. Active directions include refining genomic and imaging biomarkers to sharpen that distinction, optimizing the sequencing of androgen suppression with other therapies, and building clearer clinical guidelines for men whose disease recurs after initial treatment.
- Works
- 123,964
- Total citations
- 1,967,308
- Keywords
- Prostate CancerScreeningRadiation TherapyGleason GradingMRI ImagingAndrogen Suppression
Top papers in Prostate Cancer Diagnosis and Treatment
Ordered by total citation count.
- Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer↗ 5,711
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer↗ 5,465OA
- Decision Curve Analysis: A Novel Method for Evaluating Prediction Models↗ 5,226OA
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy↗ 4,554OA
- Biochemical Outcome After Radical Prostatectomy, External Beam Radiation Therapy, or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer↗ 4,499
- Abiraterone and Increased Survival in Metastatic Prostate Cancer↗ 4,377OA
- Screening and Prostate-Cancer Mortality in a Randomized European Study↗ 3,998OA
- Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer↗ 3,684OA
- The American Urological Association Symptom Index for Benign Prostatic Hyperplasia↗ 3,418
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer↗ 3,315
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial↗ 3,274
- EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent↗ 3,247OA
Active researchers
Top authors in this area, ranked by h-index.